Several studies have shown that discontinuation of GLP-1 receptor agonists (GLP-1 RAs) may lead to weight regain and a rebound in inflammation. To further evaluate the impact of discontinuation, a study assessed the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes receiving GLP-1 RAs (n=132,551) or sulfonylureas (n=201,136). Over a three-year follow-up, GLP-1 RA use for 2 and 2.5 years prior to discontinuation was associated with a reduced risk of MACE compared with sulfonylurea use (incidence risk ration [RR] 0.93 and 0.85, respectively).
However, discontinuation of GLP-1 RAs for 0.5 years was linked to a higher risk of MACE (RR 1.04) compared with continuous use. This risk increased gradually with longer durations of discontinuation, reaching an RR of 1.14 at one year and 1.22 at two years. Similarly, interruption of GLP-1 RA therapy (defined as…
